Lacosadel

Lacosamide, the active ingredient in Lacosadel, is a sodium channel blocker presented as an oral formulation for oral use. It is indicated as adjunctive therapy for partial‑onset seizures and primary generalized tonic‑clonic seizures in patients with epilepsy. The medication works by modulating neuronal excitability, helping to reduce seizure frequency in adults and children.

GNH USA supplies Lacosadel as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, clinics and procurement teams across multiple regions worldwide.

Lacosamide is used in the management of epilepsy, targeting seizure activity.

Partial‑onset seizures: reduces seizure frequency when added to existing antiepileptic therapy. Primary generalized tonic‑clonic seizures: provides adjunctive control of generalized seizure episodes. Epilepsy (overall): contributes to improved seizure management as part of combination therapy.

Adverse reactions may occur with Lacosamide use.

Common Side Effects: - Dizziness - Nausea - Fatigue - Headache

Serious or Rare Side Effects: - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Cardiac arrhythmia (e.g., atrioventricular block) - Severe skin reactions such as exfoliative dermatitis

When prescribing Lacosamide, clinicians should consider several safety measures. - Cardiac monitoring: assess baseline ECG and monitor for conduction abnormalities. - Hepatic function: evaluate liver enzymes before initiation and periodically thereafter. - Drug interactions: review concomitant antiepileptic and CYP‑modulating agents. - Patient counseling: advise about possible dizziness and advise caution with operating machinery. - Discontinuation: avoid abrupt cessation to reduce risk of seizure worsening. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Lacosamide may interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Carbamazepine: induces metabolism, lowering lacosamide levels. - Phenytoin: induces metabolism, reducing therapeutic exposure. - Rifampin: strong enzyme inducer that decreases lacosamide concentration.

Moderate Interactions (Monitor Closely): - Valproate: may increase lacosamide plasma levels. - Oral contraceptives: efficacy can be reduced, requiring alternative contraception methods.